As of Mar 26
| +3.44 / +6.90%|
The 30 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 50.48, with a high estimate of 63.59 and a low estimate of 39.61. The median estimate represents a -5.21% decrease from the last price of 53.26.
The current consensus among 31 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.